Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

Neurology

Volumn 80, Issue 2, 2013, Pages 196-202

  Nakasujja, Noeline ^a   Miyahara, Sachiko ^b   Evans, Scott ^b   Lee, Anthony ^b   Musisi, Seggane ^a   Katabira, Elly ^a   Robertson, Kevin ^c   Ronald, Allan ^d   Clifford, David B ^e   Sacktor, Ned ^f  

^a MAKERERE UNIVERSITY   (Uganda)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e WASHINGTON UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; PLACEBO;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDUCATIONAL STATUS; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEMORIAL SLOAN KETTERING SCALE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; UGANDA NEUROPSYCHOLOGICAL TEST BATTERY SUMMARY MEASURE;

ACTIVITIES OF DAILY LIVING; ADULT; AIDS DEMENTIA COMPLEX; ANTI-BACTERIAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPIGMENTATION; MALE; MIDDLE AGED; MINOCYCLINE; NEUROPSYCHOLOGICAL TESTS; SAMPLE SIZE; TREATMENT OUTCOME; UGANDA; YOUNG ADULT;

EID: 84873641892     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827b9121     Document Type: Article

References (31)

1. Sacktor N, Nakasujja N, Skolasky R, et al. Antiretroviral therapy improves cognitive impairment in HIV1 individuals in sub-Saharan Africa. Neurology 2006;67:311-314. (Pubitemid 44305421)
2. Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 1998;178:1000-1007. (Pubitemid 28452191)
3. Sacktor N, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV1 homosexual men. Neurology 1999;52: 1640-1647. (Pubitemid 29220641)
4. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23: 1359-1366.
5. Uganda AIDS Commission. Moving Towards Universal Access: National HIV & AIDS Strategic Plan 2007/8-2011/12. Kampala: Uganda AIDS Commission; 2007.
6. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007;68:350-355. (Pubitemid 46184210)
7. Ministry of Finance. Millennium Development Goals Report for Uganda 2010. Kampala: Ministry of Finance Planning and Economic Development; 2010.
8. UNAIDS WHO. AIDS Epidemic Update. Geneva: UNAIDS; 2010.
9. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of min-ocycline. JAMA 2005;293:2003-2011. (Pubitemid 40570894)
10. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-1410. (Pubitemid 47511461)
11. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996;40:934-940. (Pubitemid 26115227)
12. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-15774. (Pubitemid 29018775)
13. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostri-atal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98: 14669-14674. (Pubitemid 33121449)
14. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 2001;315:61-64. (Pubitemid 33049999)
15. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated neurocognitive disorders: results from a randomized trial. Neurology 2011;77:1135-1142.
16. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374. (Pubitemid 41800672)
17. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1977;3:385-401.
18. Robertson KR, Nakasujja N, Wong M, et al. Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol 2007;7:8.
19. Robertson K, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921. (Pubitemid 47329768)
20. Farag N, Rashed H, Hassan M, et al. Hepatitis C infection, cognition, and inflammation in an Egyptian sample. J Med Virol 2011;83:261-266.
21. Walusansa V, Kagimu M. Screening for hepatitis C among HIV positive patients at Mulago Hospital in Uganda. Afr Health Sci 2009;9:143-146.
22. Vinnard C, Macgregor RR. Tuberculous meningitis in HIV-infected individuals. Curr HIV/AIDS Rep 2009;6:139-145.
23. Baldewicz T, Brouwers P, Goodkin K, Kumar A, Kumar M. Nutritional contributions to the CNS patho-physiology of HIV-1 infection and implications for treatment. CNS Spectr 2000;5:61-72. (Pubitemid 30253419)
24. Nakasujja N, Skolasky RL, Musisi S, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry 2009;10:44.
25. Destache CJ. Brain as an HIV sequestered site: use of nanoparticles as a therapeutic option. In: Sharma HS, editor. Progress in Brain Research, Volume 180. New York: Elsevier; 2009:225-233.
26. Brogden R, Speight T, Avery G. Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 1975;9:251-291.
27. Si Q, Cosenza M, Kim MO, et al. A novel action of min-ocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004;10:284-292. (Pubitemid 39429939)
28. Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD41 T cells. J Infect Dis 2010;201:1132-1140.
29. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-751. (Pubitemid 39535260)
30. Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008;35:185-191. (Pubitemid 351831055)
31. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6: 1045-1053. (Pubitemid 350116691)